Categories: Technology

Patton Acquires Practical Technologies Inc. (PTI) Creating Comprehensive Electronics Manufacturing Hub in Maryland

Patton®… Let’s Connect!

The liaison creates a powerful combination of manufacturing capabilities that significantly expands capacity and services for customers across defense, aerospace, and industrial markets.

The acquisition adds PTI’s 20,000 square foot Baltimore-area manufacturing facility to Patton’s established operations in Gaithersburg, Maryland, creating a comprehensive electronics manufacturing hub. Together the companies handle everything from custom wire-and-cable, PCB assembly, electro-mechanical assembly, and epoxy and silicon potting for prototypes, low-rate or high-volume production.

“This acquisition represents a strategic investment in manufacturing capacity and capability,” said Burton Patton, Chief Revenue Officer. “By combining Patton’s engineering, design, and manufacturing capabilities with PTI’s specialized manufacturing expertise, we’re creating a one-stop solution for customers who need to innovate with excellence.”

PTI expands Patton’s advanced manufacturing capabilities with Juki pick-and-place systems, Heller reflow ovens, Nicolet real-time X-ray imaging, and automated optical inspection systems. The facility specializes in SMT and through-hole assembly, custom-cable and wire-harness manufacturing, chassis assembly, and potting/encapsulation services.

“PTI’s expertise in low volume, quick-turn PCBA manufacturing, cable assemblies and encapsulation fills some gaps for Patton,” said Robert Patton, Chief Operating Officer. “Their established processes and equipment allow us to deliver faster turnarounds and more competitive pricing while maintaining high quality standards.

Key Operational Advantages:

  • Enhanced Capacity – Additional facility enables more diverse projects without significant capital investment
  • Specialized Capabilities – Wire-harness manufacturing, potting, and encapsulation services complement core electronics manufacturing
  • Geographic Advantage – Baltimore-area location provides strategic East Coast positioning
  • Quality Systems – ISO-9001 and AS9100 certification ensures seamless integration

PTI will operate as a qualified subsidiary of Patton with its own profit-and-loss, while both companies benefit from shared resources. This approach ensures continuity of service to PTI customers while maximizing operational synergies and resilience.

“This acquisition gives Patton room to grow the Contract Services business,” said Rich Coursey, Sales Director for Patton’s Contract Services Division. “We’re building a stronger foundation for growth while better serving our customers’ evolving needs.”

Read the full-length version of this press release.

https://www.globenewswire.com/NewsRoom/AttachmentNg/144ccdb0-8247-422a-8ee0-d05774779ee4 



GlobeNews Wire

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago